Public Joint-Stock Company "Human Stem Cells Institute" (ISKJ) Historique des Prix

Public Joint-Stock Company "Human Stem Cells Institute," identified by the symbol ISKJ.ME, operates primarily as a biotechnology enterprise within Russia. The company focuses on pharmaceutical innovation, encompassing research, development, and the commercialization of its proprietary offerings in various therapeutic areas. These include regenerative medicine, bio-insurance, medical genetics (with a specific emphasis on reproductive applications), gene therapy, and biopharmaceutics. The institute manages Gemabank, a prominent family cord blood stem cell repository serving Russia and the Commonwealth of Independent States (CIS), and Reprobank, a facility for the personal cryopreservation of reproductive cells and tissues, which also facilitates sperm and oocyte donations. Among its key products is Neovasculgen, a gene-therapy medication for treating peripheral arterial disease, including critical limb ischemia. It also offers SPRS-therapy, a customized diagnostic and treatment approach designed for repairing skin damage. Furthermore, the company operates GENETICO, a specialized medical genetics center and molecular diagnostic laboratory. GENETICO delivers extensive genetic analysis and counseling services aimed at the early identification, prediction, and preventative management of genetic disorders, particularly those affecting the reproductive system. Its services extend to preimplantation genetic diagnostics and screening, involving the examination of developing embryos for hereditary monogenic conditions and chromosomal irregularities during in vitro fertilization cycles. The company additionally provides non-invasive prenatal testing to detect fetal chromosome abnormalities and is actively developing Gemacell, an investigational cell-based therapy targeting myocardial infarction. Beyond these, the firm supplies diagnostic services to uncover genetic predispositions to oncological diseases and distributes specialized equipment for cell processing. Established in Moscow, Russia, in 2003, Public Joint-Stock Company "Human Stem Cells Institute" functions as a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.

Année	Performance
2026 (TTM)	-11.26%
2025	19.53%
2024	-28.91%
2023	9.31%
2022	-41.23%
2021	213.45%
2020	153.96%
2019	72.47%
2018	-40.93%
2017	-33.88%
2016	99.08%
2015	-22.03%
2014	-67.05%
2013	31.85%
2012	21.53%
2011	-8.61%
2010	-35.96%
2009	0.00%

Année

Performance

2026 (TTM)

-11.26%

2025

19.53%

2024

-28.91%

2023

9.31%

2022

-41.23%

2021

213.45%

2020

153.96%

2019

72.47%

2018

-40.93%

2017

-33.88%

2016

99.08%

2015

-22.03%

2014

-67.05%

2013

31.85%

2012

21.53%

2011

-8.61%

2010

-35.96%

2009

0.00%

Entreprise	Prix de l'action	Variation 1a%	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$539.14	36.71%	US
Argenx SE ARGX.US	$1.04K	56.86%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Lonza Group AG LONN.SW	$761.87	7.04%	CH
Moderna, Inc. MRNA.US	$130.43	385.07%	US

Entreprise

Prix de l'action

Variation 1a%

Pays